Table 1.
Baseline characteristics according to treatment group
| Characteristic | Placebo (n = 26) | MMFS-01 (n = 25) |
| Age - y ± SD | 57.6 ± 4.4 | 57.1 ± 6.0 |
| Gender - no. (%) | ||
| Male | 8 (31%) | 7 (28%) |
| Female | 18 (69%) | 18 (72%) |
| Ethnicity - no. (%) | ||
| Hispanic | 25 (96%) | 22 (88%) |
| Non-Hispanic | 1 (4%) | 3 (12%) |
| Race - no (%) | ||
| African-American | 3 (12%) | 2 (8%) |
| Caucasian | 23 (88%) | 23 (92%) |
| Medical History - no. (%) | ||
| Cardiovascular | 10 (38%) | 9 (36%) |
| Dermatological | 0 (0%) | 3 (12%) |
| Ears/Nose/Throat/Mouth/Eyes | 6 (23%) | 6 (24%) |
| Endocrine/Metabolic | 7 (27%) | 5 (20%) |
| Gastrointestinal | 14 (54%) | 11 (44%) |
| Musculoskeletal | 8 (31%) | 12 (48%) |
| Neurological | 10 (38%) | 11 (44%) |
| Renal/Genitourinary | 1 (4%) | 5 (20%) |
| CNS Medication - no. (%) | 0 (0%) | 0 (0%) |
| Height - cm ± SD | 159.7 ± 9.7 | 161.0 ± 9.1 |
| Weight - kg ± SD | 73.2 ± 12.9 | 73.1 ± 10.4 |
| MMSE Score ± SD | 28.2 ± 1.3 | 27.8 ± 1.6 |